Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody (vol 113, pg 1062, 2009)

被引：0
|
作者：
Goldenberg
机构：
来源：
BLOOD | 2009年 / 113卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：5368 / 5368
页数：1
相关论文
共 50 条
  • [1] Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
    Goldenberg, David M.
    Rossi, Edmund A.
    Stein, Rhona
    Cardillo, Thomas M.
    Czuczman, Myron S.
    Hernandez-Ilizaliturri, Francisco J.
    Hansen, Hans J.
    Chang, Chien-Hsing
    [J]. BLOOD, 2009, 113 (05) : 1062 - 1070
  • [2] VELTUZUMAB Humanized Anti-CD20 Monoclonal Antibody Oncolytic
    Bhat, S. A.
    Czuczman, M. S.
    [J]. DRUGS OF THE FUTURE, 2011, 36 (07) : 519 - 526
  • [3] Anti-lymphoma activity of a new humanized anti-CD20 monoclonal antibody, hA20
    Goldenberg, DM
    On, ZX
    Horak, ID
    Hansen, H
    Stein, R
    [J]. FASEB JOURNAL, 2003, 17 (07): : C123 - C123
  • [4] Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
    Goldenberg, David M.
    Morschhauser, Franck
    Wegener, William A.
    [J]. LEUKEMIA & LYMPHOMA, 2010, 51 (05) : 747 - 755
  • [5] Subcutaneous Veltuzumab, a Humanized Anti-CD20 Antibody, in the Treatment of Refractory Pemphigus Vulgaris
    Ellebrecht, Christoph T.
    Choi, Eun J.
    Allman, David M.
    Tsai, Donald E.
    Wegener, William A.
    Goldenberg, David M.
    Payne, Aimee S.
    [J]. JAMA DERMATOLOGY, 2014, 150 (12) : 1331 - 1335
  • [6] Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results
    Morschhauser, F.
    Leonard, J. P.
    Fayad, L.
    Coiffier, B.
    Petillon, M.
    Coleman, M.
    Horne, H.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [7] Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL.
    Morshhauser, F.
    Leonard, J. P.
    Coiffier, B.
    Petillon, M.
    Coleman, M.
    Bahkti, A.
    Teoh, N.
    Wegener, W. A.
    Goldenberg, D. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 429S - 429S
  • [8] OBINUTUZUMAB Humanized Anti-CD20 Monoclonal Antibody Apoptosis Inducer Oncolytic
    Karlin, L.
    Salles, G.
    [J]. DRUGS OF THE FUTURE, 2011, 36 (09) : 657 - 662
  • [9] Preliminary results of a phase I/II study of the humanized anti-CD20 antibody IMMU-106 (hA20) in patients with relapsed non-Hodgkin lymphoma
    不详
    [J]. CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 339 - 341
  • [10] Subcutaneous injections of low doses of veltuzumab (humanized anti-CD20 antibody): Objective responses in B-cell malignancies
    Allen, S. L.
    Rai, K. R.
    Elstrom, R.
    Negrea, O. G.
    Farber, C. M.
    Abbasi, R.
    Teoh, N.
    Horne, H.
    Wegener, W. A.
    Goldenberg, D. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345